N
COMPANY PROFILE
NeuBase Therapeutics
Accelerating the genetic revolution developing a new class of designer synthetic medicines
Valuation
$1.3M
Market cap · 2025
Total funding
$10–50M
Disclosed equity funding
At a glance
- Founded
- 2018
- Headquarters
- Pittsburgh, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning NeuBase Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- GCGreenlight Capital
Team profiled
4
named & role-tagged
Founders
Hidden — book a demo/100
quality score
Key operators
1
quality Hidden — book a demo/100
Potential founders
Hidden — book a demo
likely future founders
Startup mafia
Hidden — book a demo
alumni-founded startups
Talent movements
Hidden — book a demo in · Hidden — book a demo out
past 12 months
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuBase Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuBase Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.